Propanc Biopharma, Inc.
PPCBNext catalyst
Phase 1 — PRP
Get an email about PPCB's next catalysts
Track Propanc Biopharma (PPCB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 2 past
Phase 1 — PRP
For advanced solid tumors (pancreatic, ovarian, refractory prostate cancers). Propanc Biopharma announced initiation of a Phase 1b first-in-human study of PRP in February 2027, a multicenter open-label trial enrolling up to 50 patients with advanced solid tumors including pancreatic, ovarian, and refractory prostate cancers.
SourceMarket Overview
Stock performance and key metrics
No drugs found in this phase.
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
When is Propanc Biopharma, Inc.'s next FDA catalyst?→
Propanc Biopharma, Inc.'s (PPCB) next tracked catalyst is a Phase 1 readout expected Feb 1, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PPCB biotech catalysts?→
Add PPCB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Propanc Biopharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
